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Role of small GPTases and {alpha}v{beta}5 Integrin in P.
aeruginosa-induced increase in lung permeability
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen that can cause severe pneumonia associated with
airspace flooding with protein-rich edema in critically ill patients. The type III secretion system is a
major virulence factor and contributes to dissemination of P. aeruginosa. However, it is still unknown
which particular bacterial toxin and which cellular pathways are responsible for the increase in lung
endothelial permeability induced by P. aeruginosa. Thus, the first objective of this study was to
determine the mechanisms by which this species causes an increase in lung endothelial permeability.
The results showed that ExoS and ExoT, two of the four known P. aeruginosa type III cytotoxins were
primarily responsible for bacterium-induced increases in protein permeability across the lung
endothelium via an inhibition of Rac1 and an activation of the RhoA signaling pathway. In addition,
inhibition of the alphavbeta5 integrin, a central regulator of lung vascular permeability, prevented these
P. aeruginosa-mediated increases in albumin flux due to endothelial permeability. Finally, prior
activation of the stress protein response or adenoviral gene transfer of the inducible heat shock protein
Hsp72 also inhibited the damaging effects of P. aeruginosa on the barrier function of lung endothelium.
Taken together, these results demonstrate the critical role of the RhoA/alphavbeta5 integrin pathway in
mediating P. aeruginosa-induced lung vascular permeability. Additionally, activation of the stress
protein response with pharmacologic inhibitors of Hsp90 may protect lungs against P.
aeruginosa-induced permeability changes.
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ABSTRACT 
Pseudomonas aeruginosa is an opportunistic pathogen that can cause severe 
pneumonia associated with airspace flooding with protein-rich edema in critically ill 
patients. The type III secretion system is a major virulence factor and contributes to 
dissemination of P. aeruginosa. However, it is still unknown which particular bacterial 
toxin and which cellular pathways are responsible for the increase in lung endothelial 
permeability induced by P. aeruginosa. Thus, the first objective of this study was to 
determine the mechanisms by which this species causes an increase in lung endothelial 
permeability. The results showed that ExoS and ExoT, two of the four known P. 
aeruginosa type III cytotoxins were primarily responsible for bacterium-induced 
increases in protein permeability across the lung endothelium via an inhibition of Rac1 
and an activation of the RhoA signaling pathway. In addition, inhibition of the αvβ5 
integrin, a central regulator of lung vascular permeability, prevented these P. 
aeruginosa-mediated increases in albumin flux due to endothelial permeability. Finally, 
prior activation of the stress protein response or adenoviral gene transfer of the inducible 
heat shock protein Hsp72 also inhibited the damaging effects of P. aeruginosa on the 
barrier function of lung endothelium. Taken together, these results demonstrate the 
critical role of the RhoA/αvβ5 integrin pathway in mediating P. aeruginosa-induced lung 
vascular permeability. Additionally, activation of the stress protein response with 
pharmacologic inhibitors of Hsp90 may protect lungs against P. aeruginosa-induced 
permeability changes. 
 
Key Words: Lung, Pseudomonas aeruginosa, Endothelial cells, Integrin, Heat Shock 
Response.  
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INTRODUCTION 
Pseudomonas aeruginosa is an opportunistic pathogen that causes lethal pneumonia 
in immunocompromised individuals and in critically ill patients (1). The high mortality of 
patients who develop P. aeruginosa pneumonia is associated with the development of 
acute lung injury, characterized by the flooding of the airspaces with a protein-rich 
edema. P. aeruginosa can cause lung damage by multiple mechanisms. Flagella, pili 
and lipopolysaccharide are the initial tethers that facilitate bacterial cell contact by 
binding the cell surface glycolipid asialo-GM1 (2). Upon cell contact, the type III 
secretion system allows P. aeruginosa to inject toxins into the cells. Four of these 
effector proteins, ExoY, ExoS, ExoT and ExoU, are known to be key determinants of 
virulence in this bacterium and can lead to host cell destruction and dissemination of P. 
aeruginosa (3, 4). Other virulence factors associated with P. aeruginosa include 
elastase, alkaline phosphatase, exotoxin A and phospholipase, secreted by the type II 
secretion system, which also participate in host-cell invasion by this bacterium (5) In 
addition, pyoverdin, pyochelin and pyocyanin, secreted metabolites associated with 
generation of reactive oxygen species, also are involved in P. aeruginosa-induced host 
cell injury (5).  
Multiple in vivo studies have shown that P. aeruginosa causes the development of 
severe alveolar pulmonary edema in rodents and that the type III secretion system plays 
a major role in the epithelial component of lung injury caused by this bacterium (6, 7). 
However, it is still unknown which particular bacterial toxin and which cellular pathways 
are responsible for P. aeruginosa-induced increase in lung endothelial permeability . 
Activation of the stress protein response (SPR) protects host cells and organs from 
otherwise lethal insults such as oxidative stress or ischemia-reperfusion injury (8). 
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Besides the classical activation of the SPR with heat or hyperthermia (also called heat 
shock), SPR can also be induced by various stimuli including corticosteroids (9), 
catecholamines (10), oxidative stress (11), and a group of compounds called 
anisomycins which includes the specific pharmacological activator, 17-allylamino-17-
demethoxy-geldanamycin [17-AAG; (12)]. Prior activation of the stress response has 
been shown to protect the lungs from damage caused by multiple noxious stimuli 
[reviewed in (13)]. However, whether SPR activation can attenuate the increase in the 
lung vascular permeability induced by a bacterial infection is unknown. 
Thus, the first objective of this study was to determine the mechanisms by which P. 
aeruginosa causes an increase in lung endothelial permeability. We found that ExoS and 
ExoT, two type III cytotoxins were responsible for the increase in protein permeability 
across the lung endothelium induced by P. aeruginosa. ExoS and ExoT previously have 
been shown to act as bi-functional toxins that contain an N-terminal RhoGAP domain 
and a C-terminal ADP-ribosylation domain (14, 15). Thus, our second objective was to 
determine the role of small GTPases Rac1 and RhoA in mediating P. aeruginosa effects 
on the lung endothelium. We found that P. aeruginosa increased paracellular 
permeability across endothelial cell monolayers via an inhibition of Rac1 and a 
subsequent activation of RhoA. In addition, we demonstrated that inhibition of the αvβ5 
integrin, which we previously have shown to be a central regulator of lung endothelial 
permeability (16), also prevented the P. aeruginosa-mediated increase in lung 
endothelial permeability. Finally, based on previously reported data, (17), the final 
objective of our studies was to determine whether prior SPR activation could prevent the 
RhoA-dependent increase in transendothelial albumin flux caused by P. aeruginosa. We 
found that prior SPR activation or the adenoviral-mediated expression of Hsp72 
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completely inhibited the paracellular permeability effect of P. aeruginosa on lung 
endothelial cell monolayers. Taken together, these results demonstrate the critical role of 
the RhoA/αvβ5 integrin pathway in mediating P. aeruginosa-induced lung vascular 
permeability.  
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MATERIALS AND METHODS 
Reagents and antibodies. All cell culture media were prepared by the University of 
California San Francisco Cell Culture Facility using deionized water and analytical grade 
reagents. Blocking studies were performed with RhoA kinase (ROCK) inhibitor (Y-27632; 
Calbiochem, San Diego, CA), anti-αvβ5 blocking (ALULA) and type specific control 
antibodies [a generous gift from Dean Sheppard, University of California San Francisco, 
CA (16)]. Primary antibody for β-catenin was obtained from Santa Cruz Biotechnology, 
CA. Rabbit polyclonal antibody to phosphotyrosine was obtained from Millipore, Billerica, 
MA. Goat anti-rabbit IgG conjugated with horse-radish peroxidase obtained from MP 
Biomedicals, Solon, OH. The compound, 17-allylamino-17-demethoxygeldanamycin (17-
AAG) was obtained from Sigma (St-Louis, MI). Texas Red-X phalloidin was obtained 
from Invitrogen Life Technologies. Lysis buffer (5x concentrate) and luciferase 
substrates were purchased from Promega (Madison, WI). The protein concentration of 
cell lysates was determined using either a Bio-Rad protein assay kit (Biorad, CA) or a 
BCA kit (Pierce, Rockford, IL). G-LISATM Rac1 and RhoA activation assay biochemistry 
kit (Cytoskeleton Inc., Denver, CO). Collagen-coated PFTE membrane Costar 
Transwells were obtained from Fisher Scientific (Santa Clara, CA). The 
chemiluminescence ECL Plus kit was obtained from Amersham Biosciences (Hercules, 
CA). 125I-labeled human serum albumin (Jeanatope ISO-TEX Diagnostics, Friendswood, 
TX) was used as radioactive tracer. Finally, 1-Palmitoyl-2-[1-14C]palmitoyl-
phosphatidylcholine, 1-[1-14C]palmitoyl-2-[1-14C]palmitoyl-phosphatidylcholine, and 1-
[1-14C]palmitoyl-2-hydroxyl phosphatidylcholine (lysophosphatidylcholine) were 
purchased from Amersham–Pharmacia Biotech (Piscataway, NJ). 1,2-Dipalmitoyl 
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phosphatidylcholine (PtPC) and 1-palmitoyl-2-hydroxyl-phosphatidylcholine (lysoPC) 
were from Avanti Polar Lipids (Alabaster, AL). 
Cell culture. Bovine pulmonary arterial endothelial cells (BPAEC; ATCC, CCL-209; 
passages all < 8) were used for the majority of experiments, as we have previously 
described (16). Bovine macrovascular lung pulmonary arterial endothelial cells were 
cultured on transwells for 4 days until they formed confluent monolayers. Confluent 
monolayers were exposed to P. aeruginosa or vehicle as described in the specific 
protocols. Cells were kept in Dulbecco's modified Eagle's medium/H21 medium 
containing 10% low endotoxin FBS and 1% penicillin/streptomycin/amphotericin in a 
humidified 95% air and 5% CO2 environment at 37 °C. In some experiments, A549 cells, 
a human alveolar epithelial cell line, were used to compare the relative cytotoxic role of 
ExoU for the alveolar epithelium and the lung endothelium. A549 cells were maintained 
in a room air/5% CO2 incubator at 37˚C using DMEM-H21 medium containing 10% fetal 
calf serum and penicillin/streptomycin (GIBCO BRL). 
Recombinant Hsp72 adenovirus. The recombinant adenovirus expressing human 
Hsp72 was a generous gift from Drs. C. Deutschman (University of Pennsylvania, 
Philadelphia, PA) and Dr. Y. Weiss [Hadassah-Hebrew University, Jerusalem; (18)]. 
Briefly, the porcine Hsp72 cDNA has been subcloned into a p73 shuttle vector with a 
human CMV promoter and recombined into an E1-E3 deleted type 5 adenoviral vector. 
The donated replication-deficient vector was then commercially amplified and purified by 
cesium chloride gradient centrifugation and PD-10 Sephadex chromatography, plaque 
tittered on 293 cells and checked for wild-type contamination (ViraQuest Inc., North 
Liberty, IA). The control vector, Ad-Empty, had no heterologous gene recombined in the 
deleted E1-E3 region.   
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Preparation of P. aeruginosa. P. aeruginosa strains used in this study are outlined 
in Table 1. All PAK strains were a kind gift from Dr. Stephen Lory at Harvard University, 
MA. PA103 strains were generously provided by Dr. Dara Frank at the Medical College 
of Wisconsin. Single and combined deletion strains of PAK and PA103 permitted 
analysis of the contribution of each of the four known P. aeruginosa type III exotoxins to 
endothelial permeability. As previously described, the ability of wild type and mutant 
bacterial strains to produce exotoxins was confirmed by Western blot using antibodies 
against ExoU, ExoS and ExoT (19). For endothelial permeability studies, strains were 
cultured overnight in 5 ml of LB medium prior to dilution with sterile PBS to a final cell 
count of 1 x 109 cells ml-1 (determined by OD600 readings). Counts were confirmed by 
serial dilution and plating on LB agar.  
Measurement of transendothelial albumin flux. Transendothelial albumin flux was 
measured as previously described (16). Briefly, cells were seeded onto 6.5 mm 
collagen-coated PFTE membrane Costar Transwells at 1 x 105 cells per well and 
cultured for 3 days. Cells were exposed to P. aeruginosa for three hours (bacterial to 
bovine cell ratio: PA103, 1:25; PAK, 1:5; PAO1, 1:5). In some experiments, cells were 
pre-treated with Y-27632 (10 μM) or its vehicle for one hour. Some cell monolayers were 
pre-treated with an anti-αvβ5 blocking or an isotype specific control antibody (10 μg/ml) 
for one hour before exposure to P. aeruginosa. During the last hour of incubation with P. 
aeruginosa strains, 125I-albumin (0.05 µCi) was applied to each upper compartment at 
37°C. After one hour, the media from the lower compartment were collected and counted 
in a Wallac Wizard γ-counter (Perkin Elmer, Shelton, CT). Only monolayers retaining 
>90% of tracer at baseline were studied. 
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Rac1 and RhoA activation assays. Rac1 and RhoA activity of endothelial cells was 
determined using a luminescence-based G-LISATM Rac1 and RhoA activation assay 
biochemistry kit according to the manufacturer's instructions. Briefly, the endothelial cells 
were grown on 35 mm cell culture dishes to 50% confluence. After serum starvation for 6 
hours, the wild-type P. aeruginosa strain PAK (bacterial to bovine cell ratio: 1:5) or its 
vehicle was placed on the cells for 10 minutes prior to harvesting of cell lysates. Lysates 
were clarified by centrifugation at 4°C (14,000 x g, 2 min), the protein concentration 
determined and final protein concentrations adjusted to 1.0 mg/ml. The lysates were 
added to plates coated with a Rac or Rho-GTP binding protein, prior to incubateion for 
30 minutes at 4oC.  Next a primary antibody specific for Rac or Rho is added and 
incubated for 45 minutes at room temperature. Lastly, an HRP-conjugated secondary 
antibody is added and incubated for 45 minutes at room temperature.  Luminescence 
was determined using the Wallac Victor 1420 (Perkin Elmer, Shelton, CT). 
Immunofluorescence for visualization of β-catenin and actin stress fibers. 
Endothelial cells were grown on collagen coated glass coverslips to confluence. Cells 
were serum starved for 6 h and pre-treated with either Y-27362 (10 μM), anti-αvβ5 
blocking Ab (10 μg/ml), control Ab (10 μg/ml) or vehicle (saline) for 1 h, then exposed to 
the wild-type P. aeruginosa strain PAK (bacterial to bovine cell ratio: 1:5) or the vehicle 
for 10 minutes to detect actin stress fibers or for 3 hours for β-catenin staining. Cells 
were then fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.5% Triton X-
100, then stained with Texas Red-X phalloidin for actin stress fibers. For β-catenin or 
αvβ5 integrin staining, cells were incubated with primary antibody for β-catenin or αvβ5 
integrin for 2 hours (1:50 dilution) at room temperature, prior to incubation with FITC 
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conjugated antibody for 1 hour (1:50 dilution) at room temperature, mounted, and 
imaged using a Leica DM5000B microscope equipped for epifluorescence. 
Immunoprecipitation for detecting phospho-β-catenin. Endothelial cells were 
grown on collagen-coated 35 mm cell culture plates to confluence. Cells were pretreated 
with either Y-27362 (10 μM), anti-αvβ5 blocking antibody (10 μg/ml), control antibody (10 
μg/ml) or vehicle (saline) for one hour and then exposed to the wild-type P. aeruginosa 
strain PAK (bacterial to bovine cell ratio: 1:5) or its vehicle for 10 minutes. Cells were 
washed twice in PBS, and then solubilized in lysis buffer (150 mM NaCl, 5 mM MgCl2, 
10 mM Tris HCl, pH 7.5, 1% Triton X-100) supplemented with a cocktail of phosphatase 
and protease inhibitors. Lysates were pre-cleared with protein G-Sepharose beads and 
incubated with 2 μg of a rabbit polyclonal antibody to β-catenin overnight at 4°C. Cell 
lysates were then incubated with protein G-Sepharose beads under continuous mixing 
for 2h at 4°C. The Sepharose-bound immune complexes were washed with lysis buffer 
and boiled in 2x Laemmli sample buffer. Proteins were separated by 7.5% SDS-PAGE, 
transferred onto nitrocellulose membranes, blocked with 5% milk in TBS containing 0.1% 
Tween-20 and incubated with the appropriate antibodies (1:1,000 dilution of rabbit 
polyclonal antibody to phosphotyrosine overnight at 4°C; 1:2,000 dilution of goat anti-
rabbit IgG conjugated with horse-radish peroxidase for 1h at room temperature). 
Immunoreactive bands were visualized using enhanced chemiluminescence. 
Cell viability assay. Cell viability was measured by the Alamar Blue assay after 
exposure to the various experimental conditions. Cell media were replaced with medium 
containing 10% Alamar Blue and placed at 37 °C in a cell incubator for 2h. The media 
were collected and read on a spectrophotometric plate reader at 530 nm. 
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Lysophospholipase assay. For the lysoPLA assay, lysophosphatidylcholine 
(lysoPC; 1-palmitoyl-2-hydroxyl-PC; 50 nmol/reaction) containing radiolabeled 1-[1 
14C]palmitoyl-2-hydroxyl-phosphoryl choline (105 cpm/reaction) was used to make lipid 
micelle assay substrate. Cell lysates from the various cell-lines (2x105 cells in 50 mM 
Tris–HCl, pH 7.4, with 0.5% Triton X-100) were added either alone (control) or with 25 
pmol of recombinant ExoU purified in Dr. J.P. Wiener-Kronish’s laboratory (20) to 50 µl 
of radiolabeled micelles and incubated for 1 hour at 37ºC in a reaction buffer (50 mM 
Tris, pH 7.4, 10 mM EDTA, 30% glycerol). The enzymatic reaction was then quenched 
by mixing with 2.5 ml Dole’s reagent (32% isopropyl alcohol/67% heptane/1% of 1N 
H2SO4, 20:5:1) and vortexed. The samples were then centrifuged for 2 min and the 
upper phase was transferred to a new tube containing 100mg silica gel. After vortexing 
and allowing the silica gel to settle, radioactivity of 200 µl of supernatant was counted by 
a liquid scintillation counter. The ratio of lysophospholipase activity on cell-line lysates 
with ExoU to the activity without ExoU was calculated. 
Superoxide dismutase measurement. Basal superoxide dismutase (SOD) activity 
was measured using a SOD assay kit (Cayman Chemical, Ann Arbor, MI) according to 
the manufacturers instructions. SOD activity (Cu/Zn, Mn, and Fe-SOD) was assessed by 
measuring the dismutation of superoxide radicals generated by xanthine oxidase and 
hypoxanthine and quantified by an SOD standard curve. One SOD unit is defined as the 
amount of enzyme needed to exhibit 50% dismutation of the superoxide radical.  
Cytotoxicity assay. In vitro cytotoxicity tests were carried out as previously 
described (21). Briefly, 2 x104 cells in culture medium were transferred to 96-well tissue 
culture plates and incubated for 18 hrs. After reaching confluence, the culture medium 
was exchanged for a medium containing either the ExoU-producing P. aeruginosa strain 
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PA103 or the ExoU-deficient PA103ΔU and applied to the cells for 4 hrs. In negative 
control wells, the medium was exchanged for fresh culture medium containing no 
bacteria. In positive control wells, 10x Trizol was added to the medium 45 minutes 
before the end of the experiment to induce maximal cell lysis. Cytotoxicity was assessed 
by the release of lactate dehydrogenase (LDH) from lysed cells using a cytotoxicity 
assay kit (Cytotox 96, Promega, Madison, WI). Cytotoxicity was expressed as a ratio of 
observed LDH release from lysed cells in experimental wells to the LDH release by 
maximally lysed cells incubated with Trizol. ExoU-specific cytotoxicity was expressed as 
the difference between the cytotoxicity due to wild type PA103 and the cytotoxicity due 
to the ExoU-deficient PA103ΔU. 
Statistical analysis. All data are summarized as mean ± SEM. One-way ANOVA 
and the Fisher’s exact t test were used to compare experimental with control groups. A p 
value of < 0.05 was considered statistically significant.  
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RESULTS 
P. aeruginosa–mediated increase in protein permeability across bovine lung 
endothelial cell monolayers is ExoS- and ExoT-dependent. Exposure to one of three 
different strains of P. aeruginosa; wildtype PA103 (secretes ExoU, ExoT and a non-
functional ExoY); wildtype PAK (secretes ExoS, ExoT and ExoY); wildtype PAO1 
(secretes ExoS, ExoT and ExoY) caused a significant increase in protein permeability 
across confluent lung endothelial cell monolayers without affecting cell viability (Figure 1 
A&B).  
The next series of experiments were designed to determine which of the known type 
III toxins played a role in P. aeruginosa–mediated increased protein permeability across 
confluent lung endothelial cell monolayers. Exposure to the wild-type P. aeruginosa 
strain PA103 or its isogenic ExoU mutant caused a significant increase in protein 
permeability across confluent lung endothelial cell monolayers (Figure 1A, 2A). In 
contrast, deletion of ExoT or the combined deletion of ExoU and ExoT in a PA103 
background inhibited the increase in protein permeability compared to that caused by 
wild-type PA103 (Figure 2A). We next examined the effect of a deletion of ExoS, ExoT 
or ExoY from wild-type PAK on the protein permeability of lung endothelial cell 
monolayers. A single deletion of ExoS, ExoT or ExoY did not affect the bacterium-
induced increase in permeability. However, the combined deletion of ExoS and ExoT or 
the triple deletion of ExoS, ExoT and ExoY inhibited the increase in protein permeability 
caused by PAK (Figure 2B). Taken together, these results indicate that the closely 
related ExoS and ExoT, but not ExoY or ExoU, in part mediate the increase in lung 
endothelial permeability caused by P. aeruginosa. 
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To understand why ExoU deletion had no effect on P. aeruginosa-induced protein 
permeability across confluent lung endothelial cell monolayers, we compared the 
cytotoxic effects of ExoU-producing P. aeruginosa strain PA103 to that of the ExoU-
deficient PA103ΔU mutant on the two cell types, A549 alveolar epithelial and lung 
endothelial cell monolayers. These results show that ExoU was significantly less 
cytotoxic for lung endothelial cells compared to the alveolar epithelial cells (Figure 3A). 
These results are likely due to a significantly lower lysophospholipase activity induced by 
ExoU exposure to lung endothelial cells compared to the activity induced after exposure 
to A549 alveolar epithelial cells (Figure 3B). Furthermore, as a recent study 
demonstrated that superoxide dismutase is an obligatory co-factor of ExoU (22), we 
measured the basal SOD activity in  lung endothelial and in the A549 alveolar epithelial 
cells. The results indicate that there was significantly less SOD activity in lung 
endothelial cells compared to that activity measured in alveolar epithelial cells (Figure 
3C). These results provide an explanation for the observed decreased toxicity of ExoU in 
lung endothelial cells. 
P. aeruginosa–mediated increase in protein permeability across bovine lung 
endothelial cell monolayers is mediated via the RhoA/αvβ5 integrin pathway. ExoS 
and ExoT from the type III secretion system of P. aeruginosa are bifunctional toxins that 
contain an N-terminal RhoGAP domain and a C-terminal ADP-ribosylation domain (14, 
15). Thus, in the next series of experiments, we evaluated the role of the small Rho 
GTPases, Rac1 and RhoA, in modulating the lung endothelial permeability induced by P. 
aeruginosa. We tested the hypothesis that the cytotoxins ExoS and ExoT inhibit baseline 
Rac1 activity required for the maintenance of the barrier function in lung endothelial 
cells, thus causing a corresponding increase in RhoA activity, as Rac1 has been shown 
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to be upstream of RhoA in regulating their reciprocal activities (23). Exposure of 
confluent lung endothelial cell monolayers to wild-type P. aeruginosa strain PAK caused 
a significant decrease in Rac1 activity and a corresponding increase in RhoA activity 
within 10 min. This effect was not observed when monolayers were exposed to the P. 
aeruginosa strain PAK with a combined deletion of ExoS and ExoT (Figure 4A & B). 
Furthermore, the increase in transendothelial albumin flux induced by PAK was blocked 
by the inhibition of ROCK, the immediate downstream effector of RhoA (Figure 4C). In 
addition, P. aeruginosa exposure induced (F)-actin to polymerize and form stress fibers, 
a cellular mechanism that precedes cell contraction and subsequent paracellular 
permeability. The formation of actin stress fibers also was blocked by exposure to a 
ROCK inhibitor prior to PAK stimulation (Figure 4D).  
Previously, we identified the αvβ5 integrin as one of the central regulators of the lung 
endothelial paracellular permeability and reported that this integrin is downstream of 
RhoA signaling and critical for the formation of actin stress fibers (16). Interestingly, P. 
aeruginosa-induced activation of RhoA was not inhibited by blocking the αvβ5 integrin, 
suggesting that RhoA signaling was upstream of the αvβ5 integrin in P. aeruginosa-
mediated signaling that leads to increased permeability in lung endothelial cells (Figure 
5A). In contrast, we found that blocking the αvβ5 integrin function inhibited the PAK-
mediated increased permeability across lung endothelial cell monolayers (Figure 5B) 
and actin polymerization (Figure 5C). To further understand the function of the αvβ5 
integrin in the endothelial barrier, cells treated or untreated with P. aeruginosa, were 
washed, fixed and both the actin filaments and αvβ5 were labeled using fluorescent-
labeled phalloidin or immunofluorescent-labeled antibodies respectively (Figure 5D).  
Endothelial cells that were not exposed to P. aeruginosa showed a diffuse staining of the 
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αvβ5 integrin that masks the fluorescent staining of the actin filaments.  In contrast, 
endothelial cells that were exposed to P. aeruginosa showed concentrations of the αvβ5 
integrin at distinct points in the cell membrane that coincided with the tip of the stress 
fibers.  These data suggest that the function of the αvβ5 integrin is to serve as an anchor 
point for the actin stress fibers that are formed following P. aeruginosa-induced 
activation of the RhoA pathway (Figure 5D).  
To further determine the mechanisms of P. aeruginosa-mediated increase in protein 
permeability, we examined whether exposure of lung endothelial cells to PAK would 
affect the phosphorylation of β-catenin, one of the critical components of the adherens 
junction protein complex. Previous studies have identified that inflammatory mediators 
such as thrombin, VEGF and TGF-β cause myosin phosphorylation, actin polymerization 
and disruption of the adherens junctions by phosphorylation of components such as β-
catenin, with subsequent degradation by the ubiquitin-proteasome system (16). Our data 
indicate that wild-type P. aeruginosa strain PAK caused phosphorylation of β-catenin in 
lung endothelial cell monolayers and that this phosphorylation was prevented by pre-
treating the cells with a ROCK inhibitor or an antibody to the αvβ5 integrin (Figure 
6A&C). Furthermore, P. aeruginosa strain PAK caused the formation of paracellular 
gaps between lung endothelial cells that was largely prevented by a pretreatment with a 
ROCK inhibitor or an antibody to the αvβ5 integrin (Figure 6B&D). Finally, the formation 
of paracellular gaps was associated with a decrease in the expression of β-catenin at 
the cell membrane, indicating a disassembly of the adherens junction complex (Figure 
6B&D). Overall, our results indicate that P. aeruginosa disrupted the adherens junctions 
and caused the contraction of endothelial cells via a RhoA/αvβ5 integrin-dependent 
mechanism leading to increased paracellular permeability. 
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SPR activation prevents P. aeruginosa–mediated increase in protein 
permeability across bovine lung endothelial cell monolayers. Because we 
previously have reported that SPR activation prevents the activation of the RhoA-
dependent VEGF-mediated increase in lung endothelial permeability (17), the final 
objective of our studies was to determine whether a prior SPR activation also would 
prevent the RhoA-dependent increase in transendothelial albumin flux caused by P. 
aeruginosa. Cell monolayers were exposed to wild-type P. aeruginosa strain PAK for 3h 
and protein permeability across these monolayers was measured with 125I-albumin. In 
some experiments, cells were stress preconditioned with heat (60 min at 43oC, then 
recovered overnight at 37oC) or pretreated with the Hsp90 inhibitor 17-AAG (10 ng/ml) 
for 8 hours before the exposure to PAK. Both of these treatments are known to increase 
the expression of Hsp 72, consistent with SPR activation. Both heat- and 17-AAG-
induced increases in Hsp72 expression (Figure 7A) and were associated with 
attenuation of the PAK-dependent increase in protein permeability across these lung 
endothelial cell monolayers (Figure 7B). In addition, stress preconditioning also reduced 
the PAK-mediated increase in cell RhoA activity (Figure 7C).  
Previous studies have reported that overexpression of the recombinant Hsp72 can 
inhibit several cell transduction pathways such as NF-κB (24) or iNOS (25-28). Thus, in 
the last series of experiments, we determined whether pretreatment of lung endothelial 
cells with an adenovirus encoding the Hsp72 (AdHSP) protein would prevent the 
increase in transendothelial albumin flux caused by P. aeruginosa. Transfection of lung 
endothelial cells with AdHSP significantly increased the expression of Hsp72 protein 
(Figure 8A) and inhibited the PAK-dependent increase in protein permeability across 
these lung endothelial cell monolayers (Figure 8B). This protective effect was absent in 
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cell lines transfected with the control virus (Figure 8B). Furthermore, transfection of lung 
endothelial cells with AdHSP also reduced the PAK-mediated increase in cell RhoA 
activity (Figure 8C). In summary, these results indicate that SPR activation or adenoviral 
gene transfer of Hsp72 interfered with the P. aeruginosa-activated cell signaling pathway 
mediated through the RhoA/αvβ5 integrin that results in protein permeability across the 
lung endothelium. 
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DISCUSSION 
P. aeruginosa is an opportunistic pathogen that causes lethal pneumonia in 
immunocompromised individuals and critically ill patients (1). The high mortality of 
patients who develop P. aeruginosa pneumonia is associated with the occurrence of 
acute lung injury, characterized by flooding of the airpaces with a protein-rich edema. 
However, the exact mechanism by which P. aeruginosa causes an increase in lung 
vascular permeability is unknown. Thus, the overall objective of this study was to 
determine the molecular mechanisms involved in the increase in lung vascular 
permeability by this bacterium. For the first time, this study shows that (a) ExoS and 
ExoT, bi-functional type III cytotoxins of P. aeruginosa, are responsible for the increase 
in protein permeability across the lung endothelium via a RhoA-dependent mechanism; 
(b) inhibition of the αvβ5 integrin, a central regulator of lung vascular permeability, 
completely prevented P. aeruginosa-mediated increase in protein permeability and (c) 
prior activation of the stress protein response attenuated the effect of P. aeruginosa on 
the barrier function of the lung endothelium by limiting the activation of the small GTPase 
RhoA. These results demonstrate a critical role for the RhoA/αvβ5 integrin pathway in 
mediating P. aeruginosa-induced increase in lung vascular permeability. 
The first objective of the present study was to determine the molecular mechanisms 
by which P. aeruginosa caused an increase in the albumin flux across lung endothelial 
cell monolayers. We found that ExoS and ExoT, but not ExoU or ExoY, are responsible 
for P. aeruginosa-mediated decrease in lung endothelium barrier function. To our 
knowledge, this is the first study to report which toxin(s) from the type III secretion 
system are responsible for increased lung endothelial barrier permeability following 
exposure to P. aeruginosa. Sayner et al. reported that a P. aeruginosa strain genetically 
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modified to only produce large amounts of ExoY, a cytoplasmic adenylate cyclase, 
caused disruption of the lung endothelial monolayers (29). That study demonstrated that 
soluble bacterial adenylate cyclases directly affected the barrier function of lung 
endothelial cells because these enzymes are not compartmentalized and not under the 
control of the phosphodiesterases (30). However, because the amount of ExoY 
produced by the engineered strain of P. aeruginosa was much larger than usually 
produced by clinical isolates, these findings may not be relevant to clinical P. aeruginosa 
infections. In fact, in the present study, deleting ExoY did not affect the ability of P. 
aeruginosa to increase protein permeability across the lung endothelium.  
The deletion of ExoU from wild-type P. aeruginosa strain PA103 did not alter 
transendothelial albumin flux. This is surprising as ExoU, a cytotoxin with phospholipase 
activity, has been shown in multiple experimental and clinical studies to be the most 
virulent toxin of P. aeruginosa (6, 7, 31). However, ExoU requires cytosolic superoxide 
dismutase as a cofactor to activate its phospholipase activity (22). Indeed, the 
abundance of superoxide dismutase in the lung epithelium and in the distal airspaces 
may render this barrier particularly susceptible to ExoU injury (32). Our results support 
this hypothesis by demonstrating that significantly greater ExoU-mediated cytotoxicity 
and lysophospholipase activity was evident in A549 epithelial cells that was associated 
with higher levels of SOD activity. In contrast, lung endothelial cells exhibited lower 
levels of cytotoxicity and lysophospholipase activity and lower levels of cytosolic SOD 
activity. Therefore, our results indicate that the lung endothelium is less vulnerable to 
ExoU than the lung epithelium and that ExoS and ExoT were more important in 
increasing endothelial permeability. 
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What are the cellular pathways by which P. aeruginosa affects the lung vascular 
protein permeability? Previous experimental work has shown that ExoS and ExoT are bi-
functional toxins that contain both an N-terminal RhoGAP domain and a C-terminal ADP-
ribosylation domain (14, 15). Thus, We tested the hypothesis that the cytotoxins ExoS 
and ExoT inhibit baseline Rac1 activity required for the maintenance of the barrier 
function in lung endothelial cells, thus causing a corresponding increase in RhoA activity, 
as Rac1 has been shown to be upstream of RhoA in regulating their reciprocal activities 
(23). Indeed, the increase in lung endothelial permeability caused by this bacterium was 
RhoA-, but not src-dependent (data not shown). This is similar to our previously reported 
results in studies examining the effect of other important mediators, such as thrombin, 
VEGF and TGF-β, on the lung endothelium (16).  
Passage of solutes through the endothelial barrier is thought to occur via a 
transcellular pathway or via receptor-activated transcytosis (33). The relative contribution 
of these pathways remains incompletely understood. However, it has been suggested 
that the formation of actin stress fibers in endothelial cells is important for the formation 
of gaps between cells. This is believed to result from imbalanced competition between 
cytoskeletal, adhesive cell-cell and cell-matrix forces that leads to an increased flux of 
solutes and protein between and across endothelial cells (33). In our experimental 
model, P. aeruginosa induced the formation of actin stress fibers via polymerization of 
(F)-actin. Furthermore, the next series of experiments showed a critical role for the αvβ5 
integrin in controlling the formation of actin stress fiber and the subsequent increase in 
lung endothelial permeability mediated by P. aeruginosa. Although our studies did not 
directly distinguish between paracellular and transcellular pathways, the ability of αvβ5 
integrin to regulate both stress fiber formation and trans-endothelial flux suggests that 
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the paracellular pathway is more relevant for the P. aeruginosa-mediated increase in 
lung vascular permeability. 
We have previously reported that SPR activation prevents the activation of RhoA-
dependent VEGF-mediated increase in lung endothelial permeability (17). Thus, the final 
objective of these studies was to determine whether a prior SPR activation would also 
prevent the RhoA-dependent increase in transendothelial albumin flux caused by P. 
aeruginosa. SPR activation was induced either with heat or with 17-AAG, a 
benzoquinone ansamycin that we have previously shown to activate stress protein 
expression (12). The results showed that SPR activation significantly decreased 
endothelial cell RhoA activity and transendothelial albumin flux induced by P. 
aeruginosa. Additionally, the overexpression of Hsp72 mediated by adenoviral 
transfection of lung endothelial cells inhibited the P. aeruginosa-mediated increase in 
lung endothelial permeability in the absence of SPR activation. Hsp72 has been shown 
to bind and inhibit expression and function of some inflammatory mediators, such as NF-
κB (24) or iNOS (25-28). Thus, in the present study, the protective effect of SPR 
activation was at least in part related to the expression of the inducible Hsp72, as both 
heat stress and 17-AAG treatment caused the expression of Hsp72 in lung endothelial 
cells. The present investigation adds to a growing number of studies, that show that SPR 
activation mediates cytoprotection in cell and animal models of acute lung injury (34-39). 
However, to our knowledge, the present work is the first study to show that prior SPR 
activation inhibits the effect of live bacteria on the lung endothelial barrier in part via the 
expression of the inducible Hsp72.  
A limitation of this series of studies is that we used cells derived from proximal 
pulmonary macrovascular endothelium. Indeed, microvascular lung endothelial cells 
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would be more relevant to study pulmonary capillary leak. However, we have previously 
reported that blocking the αvβ5 integrin in vivo protects against the increase in lung 
vascular permeability induced by ischemia-reperfusion or ventilator-induced lung injury 
in rodents (16)(17). Given these results, we suggest that the protective mechanism of 
blocking the αvβ5 integrin in macrovascular endothelium is relevant to microvascular 
endothelium such that blocking the αvβ5 integrin in microvascular cells would inhibit 
protein permeability mediated by P. aeruginosa.  Thus, taken together, these results 
demonstrate a critical role for this integrin in mediating the increase in lung endothelial 
paracellular permeability induced by exposure to P. aeruginosa. 
Clinical relevance. What is the clinical relevance of our findings? With an 
understanding of the mechanisms for lung cellular injury by P. aeruginosa new therapies 
can be proposed. If the type III secretory toxins are involved in both endothelial and 
epithelial cell injury, therapies that block this virulence mechanism would be useful in 
preventing both types of injuries. Further, the integrity of the two cellular barriers affect 
each other (40). We have previously investigated the damaging effect of P. aeruginosa 
on the distal lung epithelium. In particular, we have shown that a large amount of the P. 
aeruginosa bacteria instilled into the distal airspaces go through the distal lung 
epithelium, come in contact with the lung endothelium before reaching the bloodstream 
and cause the development of pulmonary edema (41). We have also reported that the 
i.v. administration of P. aeruginosa resulted in an increase of the vulnerability of the 
alveolar capillary barrier to an exposure to a non-toxic inoculum of the same bacterium 
instilled into the distal airspace of the lung (40). This previously published study 
demonstrated how P. aeruginosa in the circulation could amplify the minor lung epithelial 
injury caused by bacteria that colonize the distal airways. 
 24
 
In summary, these studies demonstrate for the first time the mechanisms by which P. 
aeruginosa increases lung vascular permeability. We specifically found that ExoS and 
ExoT, type III cytotoxins of P. aeruginosa, are responsible for the increase in protein 
permeability across the lung endothelium induced by this bacterium via RhoA- and αvβ5 
integrin-dependent mechanisms (Figure 9). Furthermore, prior activation of the stress 
protein response blocked the effect of P. aeruginosa on the barrier function of lung 
endothelium by preventing the activation of the small GTPase RhoA. The findings 
reported here have potential clinical relevance. Indeed, transient blockade of the αvβ5 
integrin by a humanized antibody or small RGD peptides and activation of the heat 
shock response using pharmacologic inhibitors of Hsp90 have previously been shown to 
be safe in humans (12). Therefore, these therapies may provide new potential drugs to 
treat lung injury induced by P. aeruginosa, an infection that is associated with high 
mortality in critically ill patients.  
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Table 1. Pseudomonas aeruginosa strains used in this study 
Strain Genotype Reference 
PAK Wild type P. aeruginosa encoding ExoS, ExoT and ExoY (42) 
PAKΔexoS Non-polar ExoS deletion in PAK background (42) 
PAKΔexoT Non-polar ExoT deletion in PAK background (42) 
PAKΔexoY Non-polar ExoY deletion in PAK background (42) 
PAKΔexoS/T Non-polar ExoS and ExoT deletions in PAK background (42) 
PAKΔexoS/T/Y Non-polar ExoS, ExoT and ExoY deletions 
in PAK background 
(42) 
PA103 P. aeruginosa laboratory strain encoding ExoU, ExoT and a
functional ExoY 
(6) 
PA103ΔexoU Non-polar ExoU deletion in PA103 background (43) 
PA103ΔexoT Non-polar ExoT deletion in PA103 background (4) 
PA103ΔexoU/T Non-polar ExoU and ExoT deletions in PA103 background (44) 
PAO1 Wild type P. aeruginosa encoding ExoS, ExoT and ExoY (6, 40) 
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FIGURE LEGENDS 
Figure 1. Pseudomonas aeruginosa increases protein permeability across bovine 
lung endothelial cell monolayers without affecting cell viability. Panel A. BPAEC 
cell monolayers were treated with the following Pseudomonas aeruginosa strains: 
PA103 (bacterial to bovine cell ratio: 1:25), PAK (bacterial to bovine cell ratio: 1:5) or 
PAO1 (bacterial to bovine cell ratio: 1:5) or their vehicle for 3h. Paracellular protein 
permeability was measured with 125I-albumin. All experiments were performed at least in 
triplicates and repeated three times. Data are shown as percent of controls; results are 
shown as means ± SEM; * p ≤ 0.05 from controls. Panel B. BPAEC cell monolayers 
were treated with the following Pseudomonas aeruginosa strains: PA103 (bacterial to 
bovine cell ratio: 1:25), PAK (bacterial to bovine cell ratio: 1:5) or PAO1 (bacterial to 
bovine cell ratio: 1:5) or their vehicle for 3h. Cell viability was measured with the Alamar 
Blue assay. All experiments were performed at least in triplicates and repeated three 
times. Data are shown as percent of controls; results are shown as means ± SEM. 
Figure 2. Pseudomonas aeruginosa–mediated increase in protein permeability 
across bovine lung endothelial cell monolayers is ExoS- and ExoT-dependent. 
Panel A. BPAEC cell monolayers were treated with the wild-type P. aeruginosa strain 
PA103, its isogenic mutants with single or combined deletion for ExoU, ExoT or ExoU 
and ExoT (bacterial to bovine cell ratio: 1:25) or their vehicle for 3h. Paracellular protein 
permeability was measured with 125I-albumin. All experiments were performed at least in 
triplicates and repeated three times. Data are shown as percent of controls; results are 
shown as means ± SEM; * p ≤ 0.05 from controls; ** p ≤ 0.05 from wild-type PA103. 
Panel B. BPAEC cell monolayers were treated with the wild-type P. aeruginosa strain 
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PAK, its isogenic mutants with single or combined deletion for ExoS, ExoT, ExoY or 
ExoS and ExoT or ExoS, ExoT and ExoY (bacterial to bovine cell ratio: 1:5) or their 
vehicle for 3h. Paracellular protein permeability was measured with 125I-albumin. All 
experiments were performed at least in triplicates and repeated three times. Data are 
shown as percent of controls; results are shown as means ± SEM; * p ≤ 0.05 from 
controls; ** p ≤ 0.05 from wild-type PAK. 
Figure 3. The distal lung epithelium is more susceptible than the lung endothelium 
to ExoU-mediated cytotoxicity. Panel A. A549 human alveolar epithelial and BPAEC 
cell monolayers were exposed to either ExoU-producing P. aeruginosa strain PA103 or 
the ExoU-deficient PA103ΔU for 4 hrs. Cytotoxicity was assessed by the release of 
lactate dehydrogenase (LDH) from lysed cells. Cytotoxicity was expressed as a ratio of 
observed LDH release from lysed cells in experimental wells to the LDH release by 
maximally lysed cells incubated with Trizol. ExoU-specific cytotoxicity was expressed as 
the difference between the cytotoxicity caused by wild type PA103 and ExoU-deficient 
PA103ΔU. Panel B. A549 human alveolar epithelial and BPAEC cell monolayers were 
exposed to 25 pmol of recombinant ExoU or its vehicle for one hour. Lysophospholipase 
activity was measured as described in the Methods Section. ExoU-mediated 
lysophospholipase activity was expressed as the ratio between the baseline 
lysophospholipase activity and that measured in the presence of ExoU. Panel C. Basal 
SOD activity was measured in confluent A549 human alveolar epithelial and BPAEC cell 
monolayers. SOD activity was assessed by measuring the dismutation of superoxide 
radicals generated by xanthine oxidase and hypoxanthine and quantified by an SOD 
standard curve. One SOD unit is defined as the amount of enzyme needed to exhibit 
50% dismutation of the superoxide radical. For all panels, results are shown as means ± 
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SEM; * p ≤ 0.05 from controls or from values measured in A549 cells; ** p ≤ 0.05 from 
wild-type PA103 or ExoU-treated cells.  
Figure 4. Pseudomonas aeruginosa–mediated increase in protein permeability 
across bovine lung endothelial cell monolayers is RhoA-dependent. Panel A. 
BPAEC cell monolayers were treated with the wild type P. aeruginosa strain PAK 
(bacterial to bovine cell ratio: 1:5), its isogenic mutant with a combined deletion for ExoS 
and ExoT or its vehicle for 10 min. Rac1 activity was measured as described in the 
Method section. All experiments were performed at least in triplicates and repeated three 
times. Data are shown as percent of controls; results are shown as means ± SEM; * p ≤ 
0.05 from controls; ** p ≤ 0.05 from wild-type PAK. Panel B. BPAEC cell monolayers 
were treated with the wild type P. aeruginosa strain PAK (bacterial to bovine cell ratio: 
1:5), its isogenic mutant with a combined deletion for ExoS and ExoT or its vehicle for 10 
min. RhoA activity was measured as described in the Method section. All experiments 
were performed at least in triplicates and repeated three times. Data are shown as 
percent of controls; results are shown as means ± SEM; * p ≤ 0.05 from controls; ** p ≤ 
0.05 from wild-type PAK. Panel C. BPAEC cell monolayers were treated with the wild-
type P. aeruginosa strain PAK (bacterial to bovine cell ratio: 1:5) or its vehicle for 3h. 
Some cell monolayers were pretreated with a RhoA kinase inhibitor (Y-27632) (10 μM) 
or its vehicle before exposure to PAK or its vehicle. Paracellular protein permeability was 
measured with 125I-albumin. All experiments were performed at least in triplicates and 
repeated three times. Data are shown as percent of controls; results are shown as 
means ± SEM; * p ≤ 0.05 from controls; ** p ≤ 0.05 from cell monolayers treated with 
PAK alone. Panel D. BPAEC cell monolayers were treated with the wild-type P. 
aeruginosa strain PAK (bacterial to bovine cell ratio: 1:5) or its vehicle for 10 min. Some 
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cell monolayers were pretreated with a RhoA kinase inhibitor (Y-27632) (10 μM) or its 
vehicle before exposure to PAK or its vehicle. Cells were then fixed, permeabilized and 
stained with rhodamin-phalloidin. One representative blot of 4 experiments is shown.  
Figure 5. Pseudomonas aeruginosa–mediated increase in protein permeability 
across bovine lung endothelial cell monolayers is αvβ5 integrin-dependent. Panel 
A. BPAEC cell monolayers were treated with the wild-type P. aeruginosa strain PAK 
(bacterial to bovine cell ratio: 1:5) or its vehicle for 10 min. Some cell monolayers were 
pretreated with blocking Ab to the αvβ5 integrin or isotype control Ab before exposure to 
PAK or its vehicle. RhoA activity was measured as described in Methods. Data are 
shown as percent of controls; results are shown as means ± SEM; * p ≤ 0.05 from 
controls. Panel B. BPAEC cell monolayers were treated with the wild-type P. aeruginosa 
strain PAK (bacterial to bovine cell ratio: 1:5) or its vehicle for 3h. Some cell monolayers 
were pretreated with a blocking antibody to αvβ5 integrin or its isotype control antibody 
before exposure to PAK or its vehicle. Paracellular protein permeability was measured 
with 125I-albumin. All experiments were performed at least in triplicates and repeated 
three times. Data are shown as percent of controls; results are shown as means ± SEM; 
* p ≤ 0.05 from controls; ** p ≤ 0.05 from cell monolayers treated with PAK alone. Panel 
C. BPAEC cell monolayers were treated with the wild-type P. aeruginosa strain PAK 
(bacterial to bovine cell ratio: 1:5) or its vehicle for 10 min. Some cell monolayers were 
pretreated with a blocking antibody to αvβ5 integrin or its isotype control antibody before 
exposure to PAK or its vehicle. Cells were then fixed, permeabilized and stained with 
rhodamin-phalloidin. One representative blot of 4 experiments is shown.  
Figure 6. Pseudomonas aeruginosa causes adherens junction disassembly and 
formation of paracellular gaps in bovine pulmonary arterial endothelial cell 
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monolayers. Panel A. BPAEC cell monolayers were treated with the wild-type P. 
aeruginosa strain PAK (bacterial to bovine cell ratio: 1:5) or its vehicle for 10 min. Some 
cell monolayers were pretreated with a RhoA kinase inhibitor (Y-27632) (10 μM) or its 
vehicle before exposure to PAK or its vehicle. Cells were then harvested and cell 
extracts were subjected to immunoprecipitation with an antibody against β-catenin and 
immunoblotted with an antibody to phosphotyrosine. The same blots were then reprobed 
with an antibody to β-catenin. One representative blot of 4 experiments is shown. Panel 
B. BPAEC cell monolayers were treated with the wild-type P. aeruginosa strain PAK 
(bacterial to bovine cell ratio: 1:5) or its vehicle for 3 h. Some cell monolayers were 
pretreated with a RhoA kinase inhibitor (Y-27632) (10 μM) or its vehicle before exposure 
to PAK or its vehicle. Cells were then fixed, permeabilized and incubated with a primary 
Ab against β-catenin and a FITC-conjugated secondary antibody. Panel C. BPAEC cell 
monolayers were treated with the wild-type P. aeruginosa strain PAK (bacterial to bovine 
cell ratio: 1:5) or its vehicle for 10 min. Some cell monolayers were pretreated with a 
blocking antibody to αvβ5 integrin or its isotype control antibody before exposure to PAK 
or its vehicle. Cells were then harvested and cell extracts were subjected to 
immunoprecipitation with an antibody against β-catenin and immunoblotted with an 
antibody to phosphotyrosine. The same blots were then reprobed with an antibody to β-
catenin. Panel D. BPAEC cell monolayers were treated with the wild-type P. aeruginosa 
strain PAK (bacterial to bovine cell ratio: 1:5) or its vehicle for 3 h. Some cell monolayers 
were pretreated with blocking Ab to the αvβ5 integrin or isotype control Ab before 
exposure to PAK or its vehicle. Cells were then fixed, permeabilized and incubated with 
a primary Ab against β-catenin and a FITC-conjugated secondary antibody. For all 
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experiments, one representative blot is shown. Three additional experiments gave 
comparable results. 
Figure 7. Pseudomonas aeruginosa–mediated increase in protein permeability 
across bovine lung endothelial cell monolayers is prevented by the activation of 
the heat shock response. Panel A. BPAEC cell monolayers were either treated with 
17-AAG (10 ng/ml) or its vehicle for 8 hours or were pretreated with heat (43˚C for 60 
min), then recovered overnight at 37˚C before being harvested. Control cell monolayers 
were maintained at 37˚C. The expression of Hsp72 protein was determined by Western 
blotting. One representative blot is shown. Three additional experiments gave 
comparable results. Panel B. BPAEC cell monolayers were either treated with 17-AAG 
(10 ng/ml) or its vehicle for 8 hours or were pretreated with heat (43˚C for 60 min), then 
recovered overnight at 37˚C before exposure to wild-type P. aeruginosa strain PAK 
(bacterial to bovine cell ratio: 1:5) or its vehicle for 3h. Control cell monolayers were 
maintained at 37˚C. Paracellular protein permeability was measured with 125I-albumin. 
All experiments were performed at least in triplicates and repeated three times. Data are 
shown as percent of controls; results are shown as means ± SEM; * p ≤ 0.05 from 
controls; ** p ≤ 0.05 from cell monolayers treated with PAK alone. Panel C. BPAEC cell 
monolayers were either treated with 17-AAG (10 ng/ml) or its vehicle for 8 hours or were 
pretreated with heat (43˚C for 60 min), then recovered overnight at 37˚C before 
exposure to wild-type P. aeruginosa strain PAK (bacterial to bovine cell ratio: 1:5) or its 
vehicle for 10 min. Control cell monolayers were maintained at 37˚C. RhoA activity was 
measured as described in the Method section. All experiments were performed at least 
in triplicates and repeated three times. Data are shown as percent of controls; results 
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are shown as means ± SEM; * p ≤ 0.05 from controls; ** p ≤ 0.05 from cell monolayers 
treated with PAK alone. 
Figure 8. Pseudomonas aeruginosa–mediated increase in protein permeability 
across bovine lung endothelial cell monolayers is prevented by the adenoviral 
gene transfer of Hsp72. Panel A. BPAEC cell monolayers were infected with a 
recombinant adenovirus encoding Hsp72 (MOI = 50) or an empty adenovirus and 
harvested 48hours post-infection. The expression of Hsp72 protein was determined by 
Western blotting. One representative blot is shown. Three additional experiments gave 
comparable results. Panel B. BPAEC cell monolayers were infected with a recombinant 
adenovirus encoding Hsp72 (MOI = 100) or an empty adenovirus for 48 hours and were 
then exposed to wild-type P. aeruginosa strain PAK (bacterial to bovine cell ratio: 1:5) or 
its vehicle for 3h. Paracellular protein permeability was measured with 125I-albumin. All 
experiments were performed at least in triplicates and repeated three times. Data are 
shown as percent of controls; results are shown as means ± SEM; * p ≤ 0.05 from 
controls; ** p ≤ 0.05 from cell monolayers treated with PAK alone. Panel C. BPAEC cell 
monolayers were infected with a recombinant adenovirus encoding Hsp72 (MOI = 100) 
or an empty adenovirus for 48 hours and were then exposed to wild-type P. aeruginosa 
strain PAK (bacterial to bovine cell ratio: 1:5) or its vehicle for 10 min. RhoA activity was 
measured as described in the Method section. All experiments were performed at least 
in triplicates and repeated three times. Data are shown as percent of controls; results 
are shown as means ± SEM; * p ≤ 0.05 from controls; ** p ≤ 0.05 from cell monolayers 
treated with PAK alone. 
Figure 9. Schematics of the effect of Pseudomonas aeruginosa on the lung 
endothelial barrier. Our model diagrams the P. aeruginosa-induced signaling pathway 
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that leads to an increase in lung endothelial permeability. ExoS and ExoT, two cytotoxins 
from the type III secretion system of P. aeruginosa increase lung endothelial 
permeability via the inhibition of Rac1 and the activation of the RhoA/αvβ5 signaling. 
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